Robert N. Fried Acquires 10,000 Shares of Chromadex Corp (NASDAQ:CDXC) Stock

Chromadex Corp (NASDAQ:CDXC) CEO Robert N. Fried acquired 10,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The stock was acquired at an average cost of $3.20 per share, with a total value of $32,000.00.

Shares of NASDAQ CDXC traded up $0.10 during mid-day trading on Friday, reaching $3.18. The company’s stock had a trading volume of 391,500 shares, compared to its average volume of 217,203. The firm has a market capitalization of $168.57 million, a PE ratio of -5.20 and a beta of 1.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.55 and a quick ratio of 1.11. The stock has a fifty day moving average of $3.31 and a two-hundred day moving average of $4.05. Chromadex Corp has a 52 week low of $2.68 and a 52 week high of $4.95.

Get Chromadex alerts:

Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $11.66 million. Chromadex had a negative return on equity of 147.85% and a negative net margin of 74.55%. Analysts anticipate that Chromadex Corp will post -0.51 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Northern Trust Corp boosted its stake in Chromadex by 0.7% during the second quarter. Northern Trust Corp now owns 416,911 shares of the company’s stock valued at $1,939,000 after buying an additional 3,090 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Chromadex by 8.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock valued at $425,000 after buying an additional 6,880 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Chromadex by 377.2% during the second quarter. JPMorgan Chase & Co. now owns 44,807 shares of the company’s stock valued at $208,000 after buying an additional 35,418 shares during the last quarter. Tieton Capital Management LLC boosted its stake in Chromadex by 5.1% during the second quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock valued at $6,150,000 after buying an additional 64,680 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Chromadex by 15.4% during the second quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock valued at $10,410,000 after buying an additional 298,126 shares during the last quarter. 18.29% of the stock is owned by institutional investors.

CDXC has been the subject of a number of recent analyst reports. Zacks Investment Research raised Chromadex from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Oppenheimer initiated coverage on Chromadex in a research note on Tuesday, October 15th. They issued an “outperform” rating and a $6.00 price objective for the company. Finally, ValuEngine lowered Chromadex from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $6.00.

About Chromadex

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

See Also: Growth Stocks, What They Are, What They Are Not

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.